ZYTIGA Drug Patent Profile

Which patents cover Zytiga, and what generic alternatives are available?

Zytiga is a drug marketed by Janssen Biotech and is included in one NDA.

The generic ingredient in ZYTIGA is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zytiga

A generic version of ZYTIGA was approved as abiraterone acetate by APOTEX on October 31^st, 2018.

Summary for ZYTIGA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	117
Drug Prices:	Drug price information for ZYTIGA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYTIGA
What excipients (inactive ingredients) are in ZYTIGA?	ZYTIGA excipients list
DailyMed Link:	ZYTIGA at DailyMed

See drug prices for ZYTIGA

Recent Clinical Trials for ZYTIGA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE2
Merck Sharp & Dohme LLC	Phase 3
Orion Corporation, Orion Pharma	Phase 3

See all ZYTIGA clinical trials

Pharmacology for ZYTIGA

Drug Class	Cytochrome P450 17A1 Inhibitor
Mechanism of Action	Cytochrome P450 17A1 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors

Paragraph IV (Patent) Challenges for ZYTIGA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYTIGA	Tablets	abiraterone acetate	500 mg	202379	1	2017-08-23
ZYTIGA	Tablets	abiraterone acetate	250 mg	202379	13	2015-04-28

US Patents and Regulatory Information for ZYTIGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011	AB	RX	Yes	No
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-002	Apr 14, 2017	AB	RX	Yes	Yes

Expired US Patents for ZYTIGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011

EU/EMA Drug Approvals for ZYTIGA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Ireland Limited	Abiraterone Mylan	abiraterone acetate	EMEA/H/C/005368Abiraterone Mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.	Authorised	yes	no	no	2021-08-20
Krka, d.d., Novo mesto	Abiraterone Krka	abiraterone acetate	EMEA/H/C/005649Abiraterone Krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.	Authorised	yes	no	no	2021-06-24

International Patents for ZYTIGA

See the table below for patents covering ZYTIGA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	176481
Austria	186913
Australia	3758493
Australia	668144
Australia	676088
Australia	7661894

Supplementary Protection Certificates for ZYTIGA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0633893	C300508	Netherlands		PRODUCT NAME: ABIRATERON ALSMEDE ZUURADDITIEZOUTEN EN 3-ESTERS ERVAN, IN HET BIJZONDER ABIRATERONACETAAT; NAT. REGISTRATION NO/DATE: EU/1/11/714/001 20110905; FIRST REGISTRATION:
0633893	CA 2011 00035	Denmark
0633893	91911	Luxembourg		91911, EXPIRES: 20180315
0633893	1190040-4	Sweden		PRODUCT NAME: ABIRATERON OCH SYRAADDITIONSSALTER OCH 3-ESTRAR DAERAV, SPECIELLT ABIRATERON-ACETAT; REG. NO/DATE: EU/1/11/714/001 20110905
0633893	C00633893/01	Switzerland		PRODUCT NAME: ABIRATERONI ACETAS; REGISTRATION NUMBER/DATE: SWISSMEDIC 62084 20.09.2011
0633893	11C0055	France		PRODUCT NAME: ABIRATERONE, SES SELS D'ADDITION D'ACIDE ET 3-ESTERS, EN PARTICULIER ACETATE D'ABIRATERONE; REGISTRATION NO/DATE: EU/1/11/714/001 20110905

ZYTIGA (abiraterone acetate) Market Dynamics and Financial Trajectory: Sales Momentum, Exclusivity Cliff, and Competitive Pressure

Last updated: June 23, 2026

ZYTIGA (abiraterone acetate) is a mature prostate-cancer franchise driven by earlier lines of therapy adoption, with revenue now pressured by life-cycle competition and generics risk timing for certain label segments and countries. The financial trajectory hinges on (1) how quickly new hormonal regimens displace ZYTIGA across metastatic hormone-sensitive and metastatic castration-resistant prostate cancer, (2) payer and guideline positioning versus enzalutamide and apalutamide, and (3) where ZYTIGA remains differentiated by combination use, tolerability, and persistence.

How has ZYTIGA performed financially over time and what is the revenue trajectory?

Public reporting shows ZYTIGA has transitioned from peak growth to a steady-state “franchise” phase as uptake stabilized and competitors entrenched. In most major markets, ZYTIGA growth has increasingly depended on label expansion into earlier stages, while later-line growth has faced faster switching as enzalutamide and next-generation anti-androgens gained market share.

ZYTIGA revenue drivers that still matter

• Earlier-stage metastatic prostate cancer adoption (notably metastatic castration-sensitive settings) has supported mid-cycle revenue durability.
• Continued use in metastatic castration-resistant prostate cancer (mCRPC) where ZYTIGA plus prednisone remains a recognized standard, though share is competed by enzalutamide and newer sequences.
• Combination and sequencing logic with ongoing clinical read-through influencing prescriber preference and payer coverage.

What typically pulls ZYTIGA down

• Cross-class substitution within the hormonal backbone (enzalutamide, apalutamide) as formularies narrow to preferred agents.
• Real-world treatment duration compression when patients transition earlier to alternative agents.
• Higher discounting as patents age and multiple manufacturers supply the market in many jurisdictions.

What patents protect ZYTIGA and how do they shape market exclusivity?

ZYTIGA’s long-term market protection has relied on a layered estate covering composition of matter, formulations, and method-of-use across line-of-therapy and dosing regimens. Practical exclusivity risk comes from which elements are still enforceable for each country and how many new filings exist in the local regulatory channel.

Patent estate structure (business-relevant)

Most prostate-cancer “product families” for abiraterone acetate use a layered approach:

• API and prodrug composition coverage (abiraterone acetate).
• Pharmaceutical formulation coverage (dosage form, excipients, manufacturing-critical details).
• Use patents tied to clinical states and treatment sequences (mCRPC and hormone-sensitive populations).
• Salt/crystal/process elements in specific jurisdictions.

How exclusivity is typically modeled in commercial planning

• Regulatory exclusivity (where available) can block certain approvals even where patents are expiring.
• Patent expiry and enforcement determine whether “at risk” entry is feasible for authorized generic, branded competition, or generic abiraterone products.
• Paragraph IV strategy in the US influences launch timing and litigation calendars (see below).

What is the Orange Book status of ZYTIGA and what generic entry risks exist in the US?

US launch risk for ZYTIGA has historically centered on Orange Book listings for abiraterone acetate and patent-specific challenges under the Hatch-Waxman framework. Market entry timing depends on whether challengers obtain legal clearance for specific listed patents and whether settlements carve out periods for launch.

Paragraph IV and settlement dynamics

For products like ZYTIGA, generic entrants can file under ANDA pathways with Paragraph IV certifications against one or more listed patents. The following commercial realities tend to drive risk:

• Stay periods after Paragraph IV litigation filings can delay effective launch.
• Partial settlements allow launch after a negotiated date for non-covered patents or covered method-of-use claims carve-outs.
• Injunction leverage is highest when the entrant targets composition/formulation patents rather than narrow use patents.

Generic vs “authorized” competition

When multiple ANDAs are approved but brand pricing remains anchored through contracts, market share may not shift immediately. In contrast, if biospec-like exclusivity is gone and payers open formularies to low-cost options, the shift can be rapid and earnings-accretive for generics.

When does ZYTIGA lose exclusivity and when can generics launch?

Exclusivity cliff planning requires matching:

• patent expiration dates for each Orange Book-listed patent in the relevant jurisdiction,
• regulatory exclusivity end dates (if any),
• and settlement or litigation outcomes that delay launch.

For ZYTIGA, the market reality is that many abiraterone acetate versions and competitors exist already in multiple countries, so the exclusivity question is less “whether” and more “which label segments and which patent hooks still constrain the most price-sensitive entry.”

How does ZYTIGA compare with enzalutamide and apalutamide in competitive market dynamics?

ZYTIGA competes in the same androgen-axis category as enzalutamide and apalutamide. Commercial share is driven by:

• payer preference and contracting,
• side-effect profile alignment with patient comorbidities,
• and sequencing practice based on label and clinical trial evidence.

Competitive comparison (commercially relevant)

• Enzalutamide often benefits from aggressive uptake in multiple mCRPC and earlier-line settings where formularies prefer it as the “default” next-generation agent.
• Apalutamide competes similarly in metastatic castration-sensitive and related use cases where it is positioned as another oral AR-targeting option.
• ZYTIGA differentiation typically relies on clinician comfort with its combination regimen and tolerability management, with prednisone co-administration affecting real-world use patterns.

What formulation and method-of-use patents affect ZYTIGA value most?

Even when composition patents weaken over time, formulation and method-of-use patents can delay full substitution, especially for:

• specific dosing regimens,
• distinct patient populations tied to therapeutic intent,
• and regulatory labeling tied to trial endpoints.

Formulation patents that matter commercially

Formulation IP often impacts:

• bioavailability consistency,
• manufacturing complexity,
• and product equivalence claims that underpin interchangeability.

Method-of-use patents that matter in practice

Method-of-use coverage can restrict:

• how generics label marketing (if certain “use” claims are still protected),
• and the willingness of payers to auto-substitute when a specific line-of-therapy is tied to protected claims.

What patent litigation affects ZYTIGA and how do settlements change launch timing?

US branded-generic enforcement for high-revenue oncology products usually involves:

• Paragraph IV suits against one or more listed patents,
• consolidated discovery and claim construction,
• and negotiated settlements that set a launch date tied to the “winner-take” patent(s).

For ZYTIGA, litigation outcomes shape:

• the effective date of entry of AB-rated or unbranded abiraterone products,
• and how quickly discounting accelerates in the retail and institutional channels.

What is the FDA regulatory status of ZYTIGA and how does the pathway affect competition?

ZYTIGA is an FDA-approved oncology drug product with label-based use in prostate cancer settings. Competition is influenced by:

• whether entrants pursue ANDA and get AB rating,
• labeling carve-outs under settlement,
• and how FDA labeling changes alter substitutability.

Substitutability and payer policy

Even after generic approval, payers may retain brand usage due to:

• contracting terms,
• perceived efficacy/patient-support infrastructure,
• and the cost-effectiveness of switching given administration and monitoring routines.

How does ZYTIGA’s commercial trajectory vary by geography and distribution channel?

ZYTIGA’s commercial trajectory differs by:

• local patent landscapes and expiry timing,
• regulatory approval schedules for generics,
• tender systems and hospital formularies in major markets.

Major channel dynamics

• US: share shifts depend on ANDA launch timing, pharmacy benefit contracts, and AB rating.
• EU5 and UK: pricing pressure typically intensifies after multiple generic approvals and national tender re-contracting.
• Emerging markets: entry can be faster where enforcement is weaker, shifting competition toward lowest-cost supply.

How many companies supply abiraterone acetate and what does that do to pricing?

The abiraterone acetate market commonly moves toward multi-supplier competition once enough patents and settlements allow. The financial impact is usually:

• reduced list prices via discounts,
• shrinking gross margins,
• and brand loss in share unless differentiated by contract volume or bundle economics.

What is the revenue exposure of ZYTIGA to sequencing changes in prostate cancer?

Revenue sensitivity is highest to:

• changes in guideline positioning and clinical practice patterns,
• shifts in who receives docetaxel, abiraterone, enzalutamide, or apalutamide first in metastatic hormone-sensitive disease,
• and the rate at which mCRPC patients receive AR-targeting agents earlier or in combination sequences.

Sequencing changes do not eliminate ZYTIGA uniformly; they alter:

• expected duration of use,
• patient selection,
• and the competitive “swap rate” from ZYTIGA to alternatives.

Key takeaways

• ZYTIGA’s financial path is dominated by earlier-stage uptake offset by intensifying cross-class competition and multi-supplier pricing pressure as patents age.
• US commercial risk and timing are controlled by Orange Book patent-specific status, with Paragraph IV litigation and settlements determining effective generic launch dates.
• The biggest erosion risk comes from sequencing substitution within AR-targeting therapies (enzalutamide, apalutamide), driven by payer contracting and guideline uptake.
• Formulation and method-of-use IP layers can slow substitution even when basic product protection weakens, especially where label-based use remains contested.

FAQs

1. What determines whether generic abiraterone acetate can replace ZYTIGA on a payer formulary in the US?
2. Which ZYTIGA patient subgroups are most vulnerable to switching to enzalutamide or apalutamide?
3. How do Paragraph IV stays and court timelines typically translate into commercial launch delays for abiraterone challengers?
4. What role do method-of-use patent carve-outs play in settlement agreements for high-revenue prostate cancer drugs?
5. How does international patent expiry pacing change ZYTIGA pricing in EU and emerging markets?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drugs@FDA: ZYTIGA (abiraterone acetate). US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. (n.d.). Hatch-Waxman Amendments: ANDA and Paragraph IV framework overview. US Food and Drug Administration. https://www.fda.gov/

DrugChatter Q&A for ZYTIGA

Zytiga 500 mg price in usa?
Zytiga 250 mg tablet price?
How much does zytiga cost per month?
What are the side effects of Zytiga?